Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: BTLA
Name: B and T lymphocyte associated
Location: 03q13.2
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT04773951 A Phase I Study to Evaluate the Safety Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors View
NCT05935085 This Study Will Evaluate the Safety Tolerability and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis AD View
NCT04477772 A Phase I Clinical Study of JS004 in Subjects With RecurrentRefractory Malignant Lymphoma of China View
NCT05789069 A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors View
NCT04929080 The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC View
NCT06648200 Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer View
NCT04278859 Safety Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator BTLA for Injection in Subjects With Advanced Malignancies View
NCT05891080 Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer A Randomised Controlled Open-label Phase 2 Trial View
NCT06588335 BTLA Inhibitor JS004 Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma View
NCT06256237 Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer A Phase 2 Trial View
NCT05000684 Study of JS004 Combined With Toripalimab for Advanced Lung Cancer View
NCT05123586 A IMMA Master Protocol A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus View
NCT05427396 A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody JS004 Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors View
NCT05664971 JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer View
NCT05781451 Anti-BTLA Agonist Therapy in Subjects With Primary Sjogrens Syndrome View
NCT06095583 Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer LS-SCLC View
NCT04137900 Safety Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator BTLA as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies View